

Controlled Release: spotlight innovation: GLAXOSMITHKLINE'S Ocular Drug delivery

SMI's Controlled Release conference takes place on the 20th - 21st April 2015 in London, UK.

LONDON, ENGLAND, UNITED KINGDOM, January 8, 2015 /EINPresswire.com/ -- As [controlled release](#) drug delivery systems continue to play an important role among the emerging areas of research in the treatment of diseases, the 2015 agenda sets the perfect platform with leading industry experts, as they discuss advances made in the field and novel platforms on how to overcome the challenges involved when developing long term drug delivery.

[2015 Event](#) includes a spotlight innovation: GLAXOSMITHKLINE'S Ocular Drug delivery

This [event](#) will provide the opportunity for attendees to hear GlaxoSmithKline's success on how they achieved Ocular delivery over a long period of time and how they overcame the challenges of systemic long term delivery in the eye. Ian Catchpole, Senior Investigator Senior Investigator BioPharm Innovation, GlaxoSmithKline, will discuss key areas including:

- Reducing the injection frequency to once or twice a year by using sustained release formulations of the therapeutic drug
- Evaluating the benefits of long-term controlled release insert platforms to overcome:
 - clinical burden
 - frequency issues
- Creating a formulation with adequate efficacy in a long term environment
- Reviewing how it can be used for any active drug without having to redesign the formulation or



the manufacturing process

EXPERT 2015 KEY SPEAKERS INCLUDE:

- Dr Ian Catchpole, Senior Investigator BioPharm Innovation, GlaxoSmithKline
- Professor Howard Stevens, Emeritus Professor, University of Strathclyde
- Dr Daniel Schweizer, PhD, Functional Lead, Technical Research & Development, Biologics Process R&D, Pharmaceutical Development, Novartis AG
- Teófilo Vasconcelos, Senior Formulation Scientist - Pharmaceutical Development, R&D Department, Bial
- Dr Morten Allesø, Principal Pharmaceutical Researcher, Biologics and Pharmaceutical Science, H. Lundbeck A/S
- Dr Sabine May, Scientific Assistant, Boehringer Ingelheim Pharma
- Mark Wilson, Director, Collaboration Management, Europe, Platform Technology and Science, GlaxoSmithKline
- Stephen Timothy Buckley, Senior Research Scientist, Novo Nordisk A/S

For more information or to register visit <http://www.smi-online.co.uk/2015controlledrelease37.asp>

Alternatively, contact Kinga Gradalska on +44 (0)20 7827 6192 or email kgradalska@smi-online.co.uk

----- END -----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Margaret Mugema
SMi Group Ltd
+44 (0) 20 7827 6088
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/243367335>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.